The Ministry of Health, Labor and Welfare (MHLW) on January 26 ordered label revisions to add new safety risks for two cancer drugs Pomalyst (pomalidomide) and MabCampath (alemtuzumab) by Celgene and Sanofi. For Pomalyst, the new label will add the…
To read the full story
Related Article
- MHLW to Lift Contraindication for Combined Use of Revatio/Ancaron, but Advise “Caution”
January 19, 2021
- PMDA Reviewing Safety Risks for Pomalyst, MabCampath
December 21, 2020
REGULATORY
- Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





